Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients

Nat Rev Clin Oncol. 2024 Feb;21(2):87-88. doi: 10.1038/s41571-023-00841-3.

Jakob Klemm^{1

2}, Ekaterina Laukhtina^{1

3}, Shahrokh F Shariat^{4

5

6

7

8

9}

¹ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
² Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
⁴ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
⁵ Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
⁶ Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at.
⁷ Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at.
⁸ Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at.
⁹ Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at.

No abstract available

MeSH terms